Analysts are divided on Gevo following recent earnings, with concerns over increased per-share losses despite reaffirmed revenue. The consensus price target dropped, indicating a lower future valuation for Gevo.
Gevo's growth phase is exciting, with partners ready for widespread use of sustainable resources. Bio-based technologies promise significant emission reductions. Rapid scaling not only mitigates greenhouse gas issues but also unlocks new business opportunities.
Gevo's board appointment of Katie Ellet showcases a strategic move, acknowledging her successful career in the renewable energy sector. This indicates Gevo's intent to harness her expertise while scaling their operations in the renewable fuels sector.
Gevo's expected losses increasing and revenue forecasts reducing are alarming. The unchanged consensus price target suggests no major intrinsic value shift. Despite industry-wide decline, Gevo's return to growth presents a conflicting view. High variation in analyst estimates advises against decision-making based on consensus price target.
Gevo's stock seen as a risky investment due to continuous loss and falling revenue. Poor performance over the past year flags unresolved challenges, possibly worrying potential investors. Long-term share price weakness could signal bad signs.
Gevo CEO Dr. Patrick Gruber voices trust in Shafer's ability to educate customers on petroleum alternatives due to his proven track record in the bio-based products sector. Shafer expresses enthusiasm about joining Gevo, citing its winning tech and low-carbon footprint.
Dr. Amorelli's expert skills could bolster Gevo's renewable natural gas operation and sustainable aviation fuel target, assisting in Gevo's objective to transform renewable energy and carbon into low-carbon liquid hydrocarbons.
Tonyco : Yar and blackrock main holder